“Having established proof-of-concept data from “Test tube to Mouse” in a model system we are now applying the technology in therapeutic areas where we believe we can exert a profound impact on important unmet, or poorly met, diseases”
- Colin Goddard, Ph.D. Chairman & Chief Executive Officer.
